## Luigi C Bergamaschini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4838770/publications.pdf

Version: 2024-02-01

46 papers

2,122 citations

218677 26 h-index 243625 44 g-index

46 all docs

46 does citations

46 times ranked

2560 citing authors

#	Article	IF	CITATIONS
1	Angioedema Associated With Angiotensin-Converting Enzyme Inhibitor Use. Archives of Internal Medicine, 2004, 164, 910.	3.8	184
2	Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII. Neuropsychopharmacology, 2012, 37, 1647-1655.	5.4	166
3	Peripheral Treatment with Enoxaparin, a Low Molecular Weight Heparin, Reduces Plaques and β-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2004, 24, 4181-4186.	3.6	158
4	Hereditary Angioedema: An Appraisal of 104 Cases. American Journal of the Medical Sciences, 1982, 284, 2-9.	1.1	156
5	Mild Cognitive Impairment Subtypes and Vascular Dementia in Communityâ€Dwelling Elderly People: A 3â€Year Followâ€Up Study. Journal of the American Geriatrics Society, 2006, 54, 580-586.	2.6	125
6	Long-term treatment of hereditary angioedema with attenuated androgens: A survey of a 13-year experience. Journal of Allergy and Clinical Immunology, 1991, 87, 768-773.	2.9	119
7	The Powerful Neuroprotective Action of C1-Inhibitor on Brain Ischemia-Reperfusion Injury Does Not Require C1q. American Journal of Pathology, 2004, 164, 1857-1863.	3.8	105
8	Idiopathic nonhistaminergic angioedema. American Journal of Medicine, 1999, 106, 650-654.	1.5	98
9	C1-inhibitor protects against brain ischemia–reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiology of Disease, 2005, 19, 10-17.	4.4	91
10	Pathogenetic and Clinical Aspects of C1 Inhibitor Deficiency. Immunobiology, 1998, 199, 366-376.	1.9	85
11	Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. Journal of Neurology, 2008, 255, 539-544.	3.6	76
12	Activation of the Contact System in Cerebrospinal Fluid of Patients with Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1998, 12, 102-108.	1.3	62
13	Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid- $\hat{l}^2$ in vitro. Neurobiology of Aging, 2002, 23, 531-536.	3.1	51
14	Pityriasis rubra pilaris and retinol-binding protein. British Journal of Dermatology, 1981, 104, 253-256.	1.5	50
15	Activation of complement and contact system in Alzheimer's disease. Mechanisms of Ageing and Development, 2001, 122, 1971-1983.	4.6	49
16	Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. Journal of Allergy and Clinical Immunology, 1983, 72, 294-298.	2.9	46
17	Alzheimer's Disease: Another Target for Heparin Therapy. Scientific World Journal, The, 2009, 9, 891-908.	2.1	42
18	A comprehensive evaluation of elderly people discharged from an Emergency Department. Internal and Emergency Medicine, 2008, 3, 245-249.	2.0	35

#	Article	IF	CITATIONS
19	Frailty syndrome diagnosed according to the Study of Osteoporotic Fractures criteria and mortality in older outpatients suffering from Alzheimer's disease: A one-year prospective cohort study. Aging and Mental Health, 2012, 16, 273-280.	2.8	35
20	Selective Inhibition of Plasma Kallikrein Protects Brain from Reperfusion Injury. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 849-854.	2.5	34
21	Caregiver burden as a short-term predictor of weight loss in older outpatients suffering from mild to moderate Alzheimer's disease: A three months follow-up study. Aging and Mental Health, 2010, 14, 481-488.	2.8	34
22	The region $1\hat{a}\in 11$ of Alzheimer amyloid- $\hat{l}^2$ is critical for activation of contact-kinin system. Neurobiology of Aging, 2001, 22, 63-69.	3.1	32
23	$+10\text{T/C}$ polymorphisms in the gene of transforming growth factor- $\hat{l}^21$ are associated with neurodegeneration and its clinical evolution. Mechanisms of Ageing and Development, 2007, 128, 553-557.	4.6	32
24	Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointestinal Endoscopy, 1995, 42, 301-305.	1.0	31
25	Pneumococcal colonization in older adults. Immunity and Ageing, 2016, 13, 2.	4.2	27
26	Transcriptional and epigenetic phenomena in peripheral blood cells of monozygotic twins discordant for alzheimer's disease, a case report. Journal of the Neurological Sciences, 2017, 372, 211-216.	0.6	27
27	Adverse Reactions to Influenza Vaccine Alone or with Pneumococcal Vaccine in the Elderly. Journal of the American Geriatrics Society, 2004, 52, 1219-1220.	2.6	22
28	Interaction of C1 inhibitor with thrombin on the endothelial surface. Blood Coagulation and Fibrinolysis, 2011, 22, 571-575.	1.0	22
29	The Impact of an Aging Population on the Diagnosis of Pulmonary Embolism: Comparison of Young and Elderly Patients. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 65-72.	1.7	21
30	Adenosine A2A Receptor Expression in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 20, 991-996.	2.6	20
31	Recent advances in the use of C1 inhibitor as a therapeutic agent. Molecular Immunology, 2003, 40, 155-158.	2,2	15
32	High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. Journal of Thrombosis and Thrombolysis, 2018, 45, 106-113.	2.1	14
33	Day care centre attendance and quality of life in depressed older adults living in the community. European Journal of Ageing, 2010, 7, 29-35.	2.8	12
34	First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas. Medical Oncology, 2018, 35, 15.	2.5	10
35	Adenosine A2AReceptor and IL-10 in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment. International Journal of Alzheimer's Disease, 2011, 2011, 1-6.	2.0	9
36	Prothrombotic and Inflammatory Markers in Elderly Patients with Non-Alcoholic Hepatic Liver Disease before and after Weight Loss: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 4906.	2.4	7

#	Article	IF	CITATIONS
37	AGE AND TIME SPENT IN THE EMERGENCY DEPARTMENT OF AN URBAN TEACHING HOSPITAL IN ITALY. Journal of the American Geriatrics Society, 2010, 58, 2030-2032.	2.6	4
38	Comparison of Informant Reports and Neuropsychological Assessment in Mild Cognitive Impairment. American Journal of Alzheimer's Disease and Other Dementias, 2011, 26, 528-534.	1.9	4
39	Developing a Frailty Index from routinely collected data in the Emergency Department among of hospitalized patients. European Geriatric Medicine, 2019, 10, 727-732.	2.8	3
40	Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Journal of Thrombosis and Thrombolysis, 2019, 47, 155-156.	2.1	3
41	RESPONSE LETTER TO DR. VISSER. Journal of the American Geriatrics Society, 2006, 54, 1967-1968.	2.6	2
42	Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13?ÂResults From a Pilot Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e461-e467.	0.4	2
43	Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatments. Anti-Cancer Drugs, 2021, 32, 323-329.	1.4	1
44	C1-inhibitor protects against brain ischemia/reperfusion injury via inhibition of cell recruitment and inflammation. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S47-S47.	4.3	1
45	Familial late-onset Alzheimer's disease: description of an Italian family with four affected siblings and one case of early-onset dementia in the preceding generation. Aging Clinical and Experimental Research, 2016, 28, 991-995.	2.9	0
46	A thrombotic storm. Internal and Emergency Medicine, 2017, 12, 69-73.	2.0	O